Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.60 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.60 |
| ▸ | FAP | Q12884 | 9/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7191378 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7419137 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7182285 | 0.88 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7182281 | 0.88 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7177515 | 0.86 | DPP4 (0.63) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7177518 | 0.86 | DPP4 (0.63) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6171475 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6171477 | 0.85 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7177541 | 0.83 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7177557 | 0.83 | DPP4 (0.59) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| US-6380398-B2 | COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 5/4885DPP9 3/4885 |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 5/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.